Traditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
|
|
- Priscilla Hill
- 5 years ago
- Views:
Transcription
1 Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
2 Jeff Atlin ( )
3 Standard treatment options Single drug therapies Chlorambucil (alkylating agents) Fludarabine and cladribine (nucleoside analogues) Rituximab (monoclonal antibodies) Bendamustine Bortezomib (proteasome inhibitors) Combination therapies Alkylator-rituximab Fludarabine/cladribine-based Bendamustine-based Bortezomib-based Transplantation
4 Chlorambucil Alkylating agent (cyclophosphamide, melphalan) Oral drug used for decades Many different regimens: Continuous daily dose Intermittent dosing 7-10days every month Major responses: First-line 60-70%, response duration 30 mos Slow onset (can take up to a year!) Side effects: Short term nausea, hair loss, low blood counts Long term secondary cancers, myelodysplasia (MDS)
5 Chlorambucil PROS: - Oral drug - Convenient and cheap - Well-tolerated - Lots of experience CONS: - Slow onset - Requires prolonged therapy - Risk of cancers or MDS Still used commonly worldwide but usually reserved for elderly or debilitated
6 Fludarabine and cladribine Nucleoside (NA) analogues Regimen: Intravenous (oral is available in some countries) Fludarabine daily x 5 days every month for 4-8 cycles fludarabine Major Responses: % (CR <10%) Rapid onset (<2 mos) Response durations up to 5 years
7 Nucleoside analogue side-effects Short term: Low blood counts Immune suppression unusual pneumonias (pneumocystis) and viral infections Long term: Risk of second cancers 1.6% MDS/AML and 6.2% transformed lymphoma (Leleu et al J Clin Oncol 2009;27:250-55) Stem cell toxic Immune suppression late infections even years after therapy
8 Fludarabine and cladribine PROS: Rapid onset High response rates Long response duration (>2 yrs) Shorter treatment periods CONS: Intravenous Side effects Infections Secondary MDS Stem cell toxic CR still uncommon
9 Rituximab Monoclonal antibody to CD20 3 different mechanisms for killing cancer cells Used extensively to treat various lymphomas and immune disorders Taylor et al. Nature Clin Practice Rheum (2007) 3, 86-95
10 Rituximab Regimens: Weekly infusions x 4 when used alone Also given in combination and as maintenance after chemo Major responses: 20-35% responses with short response duration Up to 58% with extended regimen (Dimopoulos; Treon) Side effects: Mostly related to infusion (shortness of breath, flushing, low BP) typically long infusions (2-6 hrs) Risk of hepatitis B flare must check before starting IgM flare (54-90%) Gertz et al Leuk Lymphoma 2004;45: Dimopoulos et al J Clin Oncol 2002;20: Treon et al Ann Oncol 2005;16:132-8
11 IgM flare with Rituximab Treon, S. P. et al. Ann Oncol : % with rituximab monotherapy Higher risk if baseline IgM 6000mg/dL or M-spike >4000mg/dL Typically occurs at 1 month, resolving by 4 months
12 Rituximab PROS: Generally well-tolerated Does not cause bone marrow suppression Particularly useful for hemolysis (failed steroids) or neuropathy No known risk of MDS or second cancers CONS: Moderately effective when used alone Infusion toxicities Expensive ($5000 per dose)
13 Bortezomib (Velcade) Proteasome inhibitor proteasome Regimen: Traditionally given IV twice weekly once weekly subcutaneous dosing now used Post- Glutamyl Site Tryptic Site Major responses: 78-85% as a single agent Rapid onset (often within 6 wks) Does not damage stem cells Bortezomib Chymotryptic Site proteasome cross-section Side effects: neuropathy (74%), low platelets, risk of shingles (herpes zoster)
14 Bortezomib PROS: Generally welltolerated Rapid responses No known risk of MDS or second cancers Not stem cell toxic No IgM flare CONS: Injection Inconvenient dosing Toxicities: Neuropathy Herpes zoster Expensive ($7500 per cycle) Not routinely available for WM in many countries
15 Bendamustine Structurally similar to alkylators and nucleoside analogues Regimen: Typically given IV for 2 days at the beginning of each 4 week cycle Major responses: 80% first-line Side effects: low blood counts, rash, infusion reactions not known to cause late cancers
16 Bendamustine PROS: Generally welltolerated does not cause hair loss Can be used in patients with kidney dysfunction No IgM flare CONS: Intravenous Inconvenient dosing Toxicities: Rash Low blood counts Long-term effects? Expensive ($4000 per cycle)
17 Combination therapies Alkylating agents with rituximab CVP-R/CPR, CHOP-R, CDR, Benda-R Nucleoside analogue combinations FC, FR, FCR CR, CCR Bortezomib combinations BR, BDR
18 Alkylator-Rituximab Combinations CVP-R: Cyclophosphamide (IV) Vincristine (IV) Prednisone (oral) Rituximab (IV) every 3-4 weeks for 6-8 cycles Side effects: Vincristine neuropathy Prednisone insomnia, diabetes, stomach upset Efficacy in indolent lymphoma: Overall responses 80% Time to progression 30 mos Doubled over CVP Marcus et al Blood 2005;105:1417
19 Should we step up CVP-R to CHOP-R? CHOP-R addition of doxorubicin (H) can cause hair loss, low counts, nausea, skin irritation CP-R vincristine can cause/worsen neuropathy Response CHOP-R (23 pts) CVP-R (16 pts) CP-R (19 pts) Overall responses 22 (96%) 14 (68%) 18 (95%) Complete responses 4 (17%) 2 (12%) 0 Time to progression 18 mos >35 mos >20 mos Ioakimidis et al. Clin Lymph Myeloma 2009;9:62
20 CDR Regimen: Cyclophosphamide orally twice daily (days 1-5) Dexamethasone IV Day 1 only Rituximab IV Given every 3 weeks for 6 months Major responses: 83% but takes 4 mos to response Side effects: Well-tolerated Minimal drops in blood counts 1/3 developed IgM flare Dimopoulos J Clin Oncol 2007;25:3344
21 Nucleoside Analogue Combinations Ref Regimen Major Resp % CR % Median Response Duration 1 FR (Fludarabine + Rituximab) TTP 51.2 mos 2 CR (Cladribine + Rituximab) TTTF 60.3 mos 3 CCR (Cladribine, cyclophosphamide + rituximab) Duration of response 58.6 mos 4 FCR EFS >77 mos 5 FCM (FC + mitoxantrone) TTF >50 mos Durable responses! But toxicities are significant low counts (prolonged), infections 1. Treon et al. Blood 2009;113: Laszlo et al. JCO 2010;28: Thomas et al. Haematologica 2007;92:PO Tedeschi et al. Cancer 2012;118: Federico et al. JCO 2013;31:1506
22 Bendamustine + rituximab Responses >90% Less toxic than CHOP-R Fewer low blood counts, infections, neuropathy, and hair loss Many now prefer Benda- R as first line therapy Progression-free survival in WM subgroup Rummel et al. Lancet 2013;381:1203
23 Progression-free rate Rituximab maintenance significantly reduces the risk of progression by 50% Patients at risk stratified HR= % CI 0.39; 0.64 p< Time (months) 82% 66% Rituximab maintenance N=505 Observation N=513 Salles et al PRIMA study ASCO 2010
24 Maintenance Rituximab Schedules End of chemo years months Best dosing schedule and duration of maintenance unclear Salles ASCO 2010 abstract Van Oers Blood 2006;108:3295 Hainsworth JCO 2005;23:1088 Ghielmini Blood 2004;103:4416 Fortspointner Blood 2006;108:4003
25 Bortezomib combinations BR (Ghobrial JCO 2010;28:1422; Ghobrial Am J Hematol June 2010 Epub) Weekly bortezomib Responses: first-line 65%, relapse 51% Only 5% severe neuropathy BDR (Treon JCO 2009;27:3830) Bortezomib twice weekly Responses: firstline 83% Time to response (1.1 mos) Severe neuropathy 30% Advantages to bortezomib combinations: Rapid onset of action No IgM flare Non-myelosuppressive, non-stem cell toxic
26 Autologous stem cell transplant Used at some institutions for young patients in relapse Must avoid stem-cell damaging chemo prior (fludarabine) EBMT review of 158 WM pts: Half relapse at 5 years Best results if still sensitive to chemotherapy and 3 prior lines of therapy (Kyriakou J Clin Oncol 2010;28:2227) Salvage chemo The patient s stem cells are collected with growth factors ± chemotherapy High-dose chemotherapy ± radiation to kill cancer cells in the bone marrow Stem cell infusion to regrow the normal bone marrow
27 Plasmapheresis (PLEX) Mechanical removal of proteins from blood One pheresis removes up to 50% IgM and reduces viscosity by 60% Temporizing measure Indications Hyperviscosity Peripheral neuropathy Bleeding related to the IgM protein Longterm PLEX may be useful (Buskard et al. CMAJ 1977)
28 How to choose? Patient considerations: Age Comorbidities (diabetes, pre-existing neuropathy, heart disease, etc) Fitness or functional level Patient location, access to hospital/clinic Patient preference Disease considerations: Low blood counts Need for rapid disease control (hyperviscosity, severe cytopenias, cryoglobulinememia) WM complications (neuropathy, hemolysis, etc)
29 General First-line Approach Older, debilitated Younger and fit Chlorambucil (Rituximab alone) Alkylator-rituximab combinations (Benda-R, CP-R, CDR) followed by maintenance rituximab Special considerations: - Low blood counts Rituximab alone - Need rapid response (i.e. hyperviscosity) fludarabine (FR) or bortezomib (BDR) combos avoid rituximab alone
30 General relapse approach Additional considerations: Choice of first-line therapy (duration of response, tolerance) Whether stem cell transplant candidate Guidelines: Consider repeat of same chemo if response >2 years If <2 years, alternate regimen Consider stem cell collection in advance of fludarabine Clinical trials
31 Summary Traditional Therapies for WM Many options available must take an individualized approach Supportive care important How do new agents like ibrutinib change the use of traditional therapies in WM?
32 Myeloma and WM Group at Princess Margaret Cancer Centre Donna Reece (head) Christine Chen Suzanne Trudel Rodger Tiedemann Vishal Kukreti Anca Prica
Waldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,
More informationThe Map of Current Treatment Options for Waldenström Macroglobulinemia
The Map of Current Treatment Options for Waldenström Macroglobulinemia Craig Reeder Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida DISCLOSURES Relevant Financial Relationship(s)
More informationTreatment of Waldenström s Macroglobulinemia Mayo Consensus
Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationI Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015
I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical
More informationCurrent Treatment Options for WM
Current Treatment Options for WM Shuo Ma, MD, PhD Northwestern University and Robert H. Lurie Comprehensive Cancer Center Waldenström s Macroglobulinemia Described by Jan Waldenström in 1944 Low grade
More informationDIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht
DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS Monique Minnema UMC Utrecht Organisation of hematological care in the Netherlands Intensive chemotherapy, including acute
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Monoclonal Antibodies Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationUpdate on Waldenström Macroglobulinemia (WM)
Update on Waldenström Macroglobulinemia (WM) Stephen M. Ansell, MD, PhD Professor of Medicine Division of Hematology Mayo Clinic Rochester, MN Update on Waldenström Macroglobulinemia (WM) Disclosures Stephen
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationClinical Commissioning Policy: Bortezomib for relapsed / refractory Waldenstrom s Macroglobulinaemia (all ages) NHS England Reference: P
Clinical Commissioning Policy: Bortezomib for relapsed / refractory Waldenstrom s Macroglobulinaemia (all ages) NHS England Reference: 170074P 1 Standard Operating Procedure: Clinical Commissioning Policy:
More informationWaldenström s Macroglobulinemia: Treatment Approach
Waldenström s Macroglobulinemia: Treatment Approach Steve Treon MD, PhD Bing Center for Waldenstrom s Macroglobulinemia Dana Farber Cancer Institute Harvard Medical School Primary Therapy of WM with Rituximab
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationCyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia Houry Leblebjian, PharmD, Kimberly Noonan, NP, Claudia Paba-Prada, MD, Steven P. Treon, MD, Jorge J.
More informationAdvances in Waldenström s Macroglobulinemia
Advances in Waldenström s Macroglobulinemia Steven. Treon, MD, hd Dana-Farber/Brigham and Women s Cancer Center Massachusetts General Hospital Cancer Center Waldenström s Macroglobulinemia first described
More informationPalliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma
Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for low grade lymphoma and Hairy Cell leukemia used in the palliative
More informationMacroglobulinemia di Waldenstrom Terapia Alessandra Tedeschi Divisione di Ematologia ASST Grande Ospedale Metropoliano Niguarda Milano
Milano 21 Aprile 2018 Macroglobulinemia di Waldenstrom Terapia Alessandra Tedeschi Divisione di Ematologia ASST Grande Ospedale Metropoliano Niguarda Milano Management of WM patient Ø IgM monoclonal gammopathy
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationFrontline treatment options in Waldenström Macroglobulinemia. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Frontline treatment options in Waldenström Macroglobulinemia Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School Disclosures Consulting Otsuka Pharmaceuticals Biogen IDEC Alexion
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationOverview on clinical trials in Waldenstrom s macroglobulinemia
trom s Overview on clinical trials in Waldenstrom s macroglobulinemia Waldenstrom s macroglobulinemia is characterized by lymphoplasmocytic cells accumulation predominantly in bone marrow, secreting immunoglobulin
More informationWaldenstrom s Macroglobulinemia (WM) Treatment Options for Recurrent WM- What Are My Choices?
Waldenstrom s Macroglobulinemia (WM) Treatment Options for Recurrent WM- What Are My Choices? IWMF Patient Education Forum June, 2016 Jeffrey V. Matous, MD Very Important Points The nature of WM is that
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationThe Immune System in Waldenstrom s Macroglobulinemia
The Immune System in Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Ontario April 2018 Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Targeted Therapies/ Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationWaldenström s macroglobulinemia: Genetic Basis and Therapy.
Waldenström s macroglobulinemia: Genetic Basis and Therapy. Steve Treon MD, MA, PhD Dana Farber Cancer Institute Harvard Medical School Boston, Massachusetts, United States Waldenström s Macroglobulinemia
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationWaldenstrom s Macroglobulinemia / Lymphoplasmacytic Lymphoma
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Waldenstrom s Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 2.2011 NCCN.org Continue Panel Members Waldenstrom s Macroglobulinemia/
More informationWaldenström s Macroglobulinemia / Lymphoplasmacytic Lymphoma
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Waldenström s Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2017 January 31, 2017 NCCN.org NCCN Guidelines for Patients available
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationWM GENOMICS AND TREATMENT OPTIONS
WM GENOMICS AND TREATMENT OPTIONS BY STEVEN P. TREON MD, PhD, FRCP Dr. Steven Treon is a Professor of Medicine at Harvard Medical School, Director of the Bing Center for Waldenstrom s Macroglobulinemia
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationInternational Waldenstrom s Macroglobulinemia Foundation: Hope, Outreach, Support, Research TREATMENT OPTIONS
International Waldenstrom s Macroglobulinemia Foundation: Hope, Outreach, Support, Research TREATMENT OPTIONS Mission Statement: To offer mutual support and encouragement to the Waldenstrom s macroglobulinemia
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationWaldenström s Macroglobulinemia Biology and Management
Waldenström s Macroglobulinemia Biology and Management Steven P. Treon, MD, MA, MS, PhD, FRCP, FACP Professor of Medicine, Harvard Medical School Director, Bing Center for WM Dana Farber Cancer Institute
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Rituximab for Mantle Cell Lymphoma g Contents Summary Summary & Background 1-2 Introduction 3 Discussion points/issues for Consideration 9 References 12 Background
More informationWALDENSTROM S MACROGLOBULINEMIA QUESTIONS AND ANSWERS
WALDENSTROM S MACROGLOBULINEMIA QUESTIONS AND ANSWERS The IWMF Vision Statement Support everyone affected by Waldenstrom's macroglobulinemia while advancing the search for a cure. The IWMF Mission Statement
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationWaldenström s macroglobulinemia (WM) is a
For reprint orders, please contact reprints@expert-reviews.com Novel treatment regimens for Waldenström s macroglobulinemia Expert Rev. Hematol. 3(3), 339 350 (2010) Ramón García-Sanz 1 and Enrique M Ocio
More informationNuove opportunità di cura. Stefano Sacchi, Modena
Nuove opportunità di cura Stefano Sacchi, Modena Antiangiogenesis therapies The goal is to target the blood supply that feeds tumors. Vorinostat (suberoylanilide hydroxamic acid - SAHA) TOPIC SEARCH:
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More informationMaintenance rituximab following response to first-line therapy in mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Maintenance rituximab following response to first-line therapy in mantle cell lymphoma Maintenance rituximab following response to first-line therapy in mantle
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationAHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.
AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationWaldenstrom macroglobulinemia: prognosis and management
OPEN Citation: (2015) 5, e394; doi:10.1038/bcj.2015.28 www.nature.com/bcj REVIEW : prognosis and management This article has been corrected since Online Publication and an erratum has also been published
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationSecond Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda, 1 Joseph Mikhael, 2 Andrew Winter, 1 Norman
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationClinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages) NHS England Reference: 17088P NHS England INFORMATION READER BOX Directorate Medical
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationObinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma
Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma 1 st Appraisal Committee meeting Background and Clinical Effectiveness Committee A Lead team John Watkins
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationFollicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More information